Oncology trials are some of the most complex in clinical research—slow enrollment, operational inefficiencies, and limited access continue to hold studies back. But change is here, thanks to evolving regulations and decentralized trial methodologies.
With new FDA guidance on Direct-to-Patient (DTP) models, ePROs, and Digital Health Technologies (DHTs), the industry has a rare opportunity to reshape oncology research for speed, scalability, and patient-centricity.
The momentum is undeniable:
97% growth in DHT adoption over the last 5 years (PwC)
Digital endpoint collection doubling every 3 years since 2015 (Tufts)
Moving forward, it’s critical to have an optimized strategy that defines how you collect the right data to improve study quality and experiences.
Leading pharma companies are already leveraging DHTs, ePROs, and clinical trial platforms to slash timelines, improve data integrity, and simplify trial execution—are you?
Join us to learn how the top 10 pharma companies are redefining their oncology digital strategy. Register now!
Key Takeaways
The must-ask questions to shape a winning digital strategy for your clinical development program.
How digital biomarkers and measures are fast-tracking clinical development timelines.
Real-world success: How top pharma companies use Medable’s cutting-edge tech to speed up oncology trial decisions.